AVNS VS NVO Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatilityAnalyst Price Targets
PerformanceSentimentTechnicalsEarningsProfitVolatilityAnalyst Price Targets

Performance

AVNS
10/100

AVNS returned -19.03% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NVO
100/100

NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.

Sentiment

AVNS
86/100

AVNS had a bullish sentiment score of 85.83% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 0.00 likes per day.

NVO

"Sentiment" not found for NVO

Technicals

AVNS
61/100

AVNS receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.

NVO
50/100

NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

AVNS
10/100

AVNS has missed earnings 6 times in the last 20 quarters.

NVO
46/100

NVO has missed earnings 3 times in the last 20 quarters.

Profit

AVNS
46/100

Out of the last 20 quarters, AVNS has had 8 profitable quarters and has increased their profits year over year on 7 of them.

NVO
90/100

Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.

Volatility

AVNS
46/100

AVNS has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

NVO
53/100

NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Analyst Price Targets

AVNS

"Analyst Price Targets" not found for AVNS

NVO
50/100

1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.

All score calculations are broken down here to help you make more informed investing decisions

Avanos Medical, Inc. Summary

New York Stock Exchange / AVNS
Healthcare
Medical - Devices
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Novo-Nordisk A/S Summary

New York Stock Exchange / NVO
Healthcare
Biotechnology
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.